Literature DB >> 11850286

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.

P Richard Harrigan1, Brendan A Larder.   

Abstract

The phenomenon of cross-resistance to antiretroviral agents used to treat human immunodeficiency virus type 1 infection is well known but so far has been only qualitatively described. Here, we quantitate the degree of cross-resistance among all commonly prescribed antiretroviral agents in almost 5,000 clinically derived recombinant isolates collected in the United States since January 2000.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850286      PMCID： PMC127474          DOI： 10.1128/AAC.46.3.909-912.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  International perspectives on antiretroviral resistance. Resistance to protease inhibitors.

Authors:  V Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 2.  International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

Authors:  C Loveday
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 3.  International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  S G Deeks
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

4.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 5.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

Authors:  J E Kaplan; D Hanson; M S Dworkin; T Frederick; J Bertolli; M L Lindegren; S Holmberg; J L Jones
Journal:  Clin Infect Dis       Date:  2000-04       Impact factor: 9.079

Review 6.  Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.

Authors:  R Swanstrom; J Erona
Journal:  Pharmacol Ther       Date:  2000-05       Impact factor: 12.310

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  Natural history of HIV infection in the era of combination antiretroviral therapy.

Authors:  R D Moore; R E Chaisson
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177
  9 in total
  9 in total

Review 1.  Antiretroviral therapy in Africa.

Authors:  Warren Stevens; Steve Kaye; Tumani Corrah
Journal:  BMJ       Date:  2004-01-31

2.  A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase.

Authors:  Trevor Hinkley; João Martins; Colombe Chappey; Mojgan Haddad; Eric Stawiski; Jeannette M Whitcomb; Christos J Petropoulos; Sebastian Bonhoeffer
Journal:  Nat Genet       Date:  2011-03-27       Impact factor: 38.330

3.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Authors:  P R Harrigan; M D Miller; P McKenna; Z L Brumme; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 5.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

Review 6.  Breast-feeding and Transmission of HIV-1.

Authors:  Grace John-Stewart; Dorothy Mbori-Ngacha; Rene Ekpini; Edward N Janoff; John Nkengasong; Jennifer S Read; Phillippe Van de Perre; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

7.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

Authors:  Kathleen M Doherty; Priyanka Nakka; Bracken M King; Soo-Yon Rhee; Susan P Holmes; Robert W Shafer; Mala L Radhakrishnan
Journal:  BMC Bioinformatics       Date:  2011-12-15       Impact factor: 3.169

9.  Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1.

Authors:  Robert Polster; Christos J Petropoulos; Sebastian Bonhoeffer; Frédéric Guillaume
Journal:  Mol Biol Evol       Date:  2016-09-27       Impact factor: 16.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.